tbuckley/cabot-search huggingface dataset:
Vigilancia de la gripe en los países miembros de la red europea EISS entre octubre de 2000 y abril de 2001
Authors: K Mantey, A Mosnier, W J Paget
Journal: Eurosurveillance (2001)

En los paises cubiertos por el Sistema Europeo de Vigilancia de la Gripe (European Influenza Surveillance Scheme; EISS), el invierno 2000-2001 estuvo marcado principalmente por la circulacion de virus de la gripe A(H1N1). La gripe B, que globalmente represento una minoria de casos, se extendio en una fase posterior de la temporada y predomino en Gran Bretana, Irlanda y Portugal. La actividad gripal alcanzo su nivel maximo en el periodo comprendido entre enero y febrero/marzo de 2001, registrandose poco retraso entre paises (maximo cuatro semanas). En general, las tasas de incidencia declaradas fueron muy inferiores a las de la temporada anterior, lo que indica un nivel moderado de actividad gripal.
Abstract 20940: PKA-Phosphorylation of Hsp20 Promotes Cardiac Fibrosis Through Upregulation of IL-6
Authors: George Gardner, Josh Travers, Guan-Sheng Liu, Jiang Qian, Min Jiang, Nathan Robbins, Jack Rubinstein, Burns Blaxall, Guo-Chang Fan, Evangelia Kranias
Journal: Circulation (2017)

Introduction: Heat shock protein 20 (Hsp20) is the only small heat shock protein that can be phosphorylated by PKA upon β-adrenergic stimulation. Interestingly, phosphorylation of Hsp20 is highly elevated following I/R injury and in human heart failure. However, the functional significance of this phosphorylation in vivo is currently unclear. Results: Transgenic lines with cardiac overexpression of constitutively phosphorylated Hsp20 (S16D) were generated and we chose one with 10-fold overexpression to mimic the levels observed in human failing hearts. Longitudinal assessment of cardiac function via echocardiography indicated significantly reduced LVEF in S16D mice starting at 3 months of age which progressed to heart failure and early lethality (50% dead by six months). Histological examination revealed interstitial fibrosis as early as 2 months with no evidence of apoptosis. To elucidate the mechanisms underlying fibrosis in S16D hearts, we performed cardiomyocyte-fibroblast crosstalk experiments. Adult mouse cardiomyocytes were infected with GFP, S16D or S16A-Hsp20, cultured for 48 hours, and their supernatant was then used to culture adult mouse fibroblasts. S16D-cultured fibroblasts exhibited enhanced proliferation as well as pro-fibrotic signaling (increased expression of α-SMA, TGF-β and collagen as well as cytokines IL-6 &amp; IL-1β), while GFP or S16A-cultured fibroblasts showed no alterations. At the sub-cellular level, Stat3 phosphorylation and nuclear translocation was increased in S16D-cultured fibroblasts. These pro-fibrotic effects were associated with increased expression and secretion of IL-6 from cardiomyocytes, which were inhibited by inclusion of an IL-6 neutralizing antibody to the S16D-myocyte supernatant upon fibroblast exposure. Consistent with our ex-vivo results, the cardiac levels of IL-6 as well as Stat3 activation were upregulated in S16D hearts at two months, concurrent with increased IL-6 levels in the serum. Conclusion: Phosphorylation of Hsp20 (P-Hsp20) in cardiomyocytes appears to contribute to fibrosis and ventricular remodeling via upregulation of IL-6. Thus, targeting the observed increases in failing hearts may hold therapeutic potential.
Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia
Authors: Ehsan Ghorani, Baljeet Kaur, Rosemary A Fisher, Dee Short, Ulrika Joneborg, Joseph W Carlson, Ayse Akarca, Teresa Marafioti, Sergio A Quezada, Naveed Sarwar, Michael J Seckl
Journal: The Lancet (2017)
P2.05-016 Clinical Importance and Application of New T Descriptors in the 8th TNM Classification for Pathological T0-1 Lung Adenocarcinoma
Authors: M. Nakao, H. Ninomiya, J. Ichinose, M. Mun, K. Nakagawa, Y. Ishikawa, S. Okumura
Journal: Journal of Thoracic Oncology (2017)
TAS-115, a potent MET/VEGFRs-targeted kinase inhibitor with high tolerability, to suppress NSCLC-driven bone disruption.
Authors: Hidenori Fujita, Akira Gomori, Motomu Sakuragi, Akihiro Hashimoto, Kenjiro Ito, Takamasa Suzuki, Yayoi Fujioka, Kazuhiko Yonekura, Takekazu Aoyama, Nobuaki Matsubara, Toshihiko Doi, Yoshikazu Iwasawa
Journal: Journal of Clinical Oncology (2015)

e22011 Background: Bone metastasis is a crucial issue for patients with late-stage cancer as it impairs QOL and shortens survival. Bisphosphonates, anti-RANKL antibody and 223RaCl2are approved agents managing skeletal-related events, but effects on survival are limited. Cabozantinib is a MET/VEGFRs kinase inhibitor effective against bone lesions in castrate-resistant prostate cancer patients and is associated with increased PFS but no change in overall survival in a phase III study. We assumed that higher tolerability and potency of kinase inhibitors are required to prolong survival. This study characterizes the efficacy and tolerability of TAS-115. Methods: A mouse bone metastasis model was created via intratibial injection of luciferase-transfected human lung adenocarcinoma cell line (A549-luc-BM1). TAS-115 and cabozantinib were administered orally with daily dosing. Tumor growth and bone morphology were evaluated by bioluminescence imaging, micro-CT, and histopathological analysis. Results: TAS-115 inhibited MET gene-amplified tumor cell and VEGF-dependent endothelial cell growth by inhibiting MET and VEGFRs. This effect was 300-1000-fold weaker in MET- and VEGFR-signal independent cells than in those dependent cells. These data indicate TAS-115 is a potent MET/VEGFRs-targeted kinase inhibitor with minimal off-target effects. TAS-115 significantly suppressed tumor growth and bone disruption in an A549-luc-BM1 bone metastasis model and did not affect body weight, even at a 66-fold higher dose over the minimum effective dose. However, cabozantinib inhibited tumor growth, but bone lesion effect was partial, even at MTD. Micro-CT analysis showed TAS-115 completely suppressed tumor-induced bone disruption to almost the same level as normal bone. Histopathological analysis demonstrated TAS-115 decreased Ki-67 positive cells and CD31-positive vessels within tumor tissue and decreased tumor-induced osteoclasts in tibiae. Moreover, 18FDG-PET signal in bone lesion decreased after treatment with TAS-115 in a phase I clinical trial, suggesting it is effective in bone metastasis patients. Conclusions: TAS-115 is a promising agent for treating bone metastasis.
Diagnósticos de las infecciones de transmisión sexual no virales en Lituania y recomendaciones internacionales
Authors: A Vagoras, R Butylkina, V Juseviciute, A Hallén, M Unemo, M Domeika
Journal: Eurosurveillance (2006)

El objetivo del siguiente estudio, realizado de septiembre 2002 a diciembre de 2003, fue evaluar la calidad y disponibilidad de los laboratorios de diagnostico de las infecciones de transmision sexual no virales (ITS), es decir, las producidas por C. trachomatis, N. gonorrhoeae, T. vaginalis y T. Pallidum en Lituania. 
Los datos de vigilancia describiendo la organizacion y las caracteristicas de los servicios de diagnosticos de las ITS en Lituania se recogieron mediante un cuestionario, seguidos de visitas. Para evaluar la calidad de los diagnosticos de ITS se utilizaron las recomendaciones internacionales basadas en evidencias.
Existian 171 centros de salud con servicios de diagnosticos de las ITS para los 3,5 millones de habitantes de Lituania. Sin embargo, solamente el 6% (n=9) de los que respondieron (n=153) tenian un diagnostico de confirmacion segun las recomendaciones internacionales, para todas las ITS de interes en Lituania (C. trachomatis, N. gonorrhoeae, T. pallidum, y T. Vaginalis). Ademas el acceso a esos servicios variaba mucho entre las provincias. Algunos tenian muy pocas muestras analizadas cada ano y en general el numero de muestras era muy escaso, especialmente para el diagnostico de C. trachomatis.
En Lituania, es muy importante optimizar tanto el diagnostico de estas ITS como la vigilancia epidemiologica y el manejo de dichas infecciones. Una solucion podria ser disminuir el numero de laboratorios, facilitando asi la optimizacion de los diagnosticos de ITS en los laboratorios que permanecieran, mediante la aplicacion de las recomendaciones internacionales, estandarizacion, y controles de calidad internos y externos sistematicos. Ademas, se recomienda implementar redes nacionales de laboratorios y Centros nacionales de referencia para estas ITS.
Personalized Medicine: Engineered Paper‐Based Cell Culture Platforms (Adv. Healthcare Mater. 22/2017)
Authors: Darlin Lantigua, Yan Ni Kelly, Baris Unal, Gulden Camci‐Unal
Journal: Advanced Healthcare Materials (2017)

Engineered paper-based cell culture platforms demonstrate great promise for personalized medicine, diagnostics, disease models, organ-on-paper systems, and tissue origami and engineering. Gulden Camci-Unal and co-workers provide an overview of engineered paper-based platforms for culture and analysis of various types of cells in article number 1700619.
Impact of palliative care referral on hospice enrollment: A single center analysis.
Authors: Shreya Sinha, Alina Basnet, Wajihuddin Syed, Pallavi Koparthy, Rashad Khan, Bhaskara Reddy Madhira, Danning Huang, Sheila M. Lemke
Journal: Journal of Clinical Oncology (2017)

17 Background: Despite ASCO’s recommendation to introduce palliative care services for all patients diagnosed with localized or metastatic pancreatic cancer, most patients’ care does not involve this multimodality approach. Transitioning patients to hospice at an appropriate time is essential in oncologic practice. The purpose of this study is to identify which variables affect acceptance of hospice services by patients. Methods: A retrospective chart review of patients with pancreatic cancer treated at Upstate University Hospital from 2011-2015 was performed. We studied variables including age, sex, race, stage, insurance status, advance directives, performance status and laboratory values. We analyzed patients based on acceptance or rejection of hospice care in their disease course and conducted a univariate analysis on different factors to determine predisposing variables. p-values were calculated using Chi-Square test and t-test. Results: We reviewed 325 patients charts and found statistically significant relation to acceptance of hospice and insurance status, and involvement of palliative care in their care. Patients with Medicare were more likely to decline hospice care whereas patients with Medicaid or no insurance were more likely to accept it. 36.23% of patients saw palliative care services at any point in their treatment course and these patients were more likely to accept hospice care than patients who did not (p = &lt; 0.0001). Patients who were seen by palliative care earlier in their disease course were more likely to accept hospice care, although this did not reach statistical significance (p = 0.0731). Patients with stage IV disease were more likely to accept hospice care (p = 0.0095). Other variables like presence of advanced directives, tumor markers, age, and sex did not have a significant impact. Conclusions: Palliative care involvement is beneficial in patients with pancreatic cancer as they face a rough disease course with multiple treatment and disease related morbidities. Patients with early palliative care involvement during their illness are more likely to decide on hospice care at the end stages of their malignancies. This supports early palliative care introduction as an adjunct to oncologic care.
The evolutionary history of lethal metastatic prostate cancer
Authors: G Gundem, P Van Loo, B Kremeyer, L B Alexandrov, Tubio Jmc., E Papaemmanuil, D S Brewer, H Kallio, G Hognas, M Annala, K Kivinummi, V Goody, C Latimer, S O'Meara, K J Dawson, W Isaacs, M R Emmert-Buck, M Nykter, C Foster, Z Kote-Jarai, D Easton, H C Whitaker, D E Neal, C S Cooper, R A Eeles, T Visakorpi, P J Campbell, U McDermott, D C Wedge, G S Bova
Journal: Cancer Research (2015)
Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension
Authors: Robert M. Califf
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Overcoming recruitment challenges in a randomized clinical trial of early palliative care.
Authors: Susanne Zwahlen, Monica Fliedner, Steffen Eychmüller
Journal: Journal of Clinical Oncology (2017)

140 Background: Reasons why clinical trials of early palliative care (ePC) interventions have prolonged patient recruitment time frames have been researched mainly qualitatively. Our objective was to identify major recruitment barriers encountered in our ePC trial, as well as to implement actions to overcome them. The impact of these changes on recruitment was measured. Methods: Data from all patients screened at the main study site (Inselspital, University Hospital Bern) between October 2013 and April 2016 were prospectively analyzed for: date of contact, reporting department, eligibility status, as well as consent status. Data until march 2014 was used to identify the main recruitment barriers. Starting in march 2014 changes to the recruitment process were implemented and all data from then onwards was used to estimate the impact of these adaptations. Results: The three main barriers identified were: Logistic, motivational, or related to eligibility criteria. Logistic barriers were overcome by changing from voluntary referral by the treating physician to systematically screening outpatient clinics of medical oncology, radio-oncology, gyneco-oncology and the internal medicine ward. Motivational barriers were addressed through education and dedicated study staff. Eligibility criteria were widened to include pancreatic and urothelial cancer. The actions implemented increased the accrual rate from one patient during a five month period to 2,8 patients per month. The widening of the eligibility criteria contributed to this result by recruiting 0,5 patients per month. The implementation of a systematic screening procedure increased the number of eligible patients invited to participate from one per month to 4,8 per month. An increase in the study consent rate from 20 % to 58 % can be translated into an increased acceptance of early palliative care. Conclusions: Education and dedicated study staff in order to increase the acceptance of ePC as well as a tool to identify eligible patients in a time-efficient manner improved patient recruitment in our ePC trial. We suggest that these factors can be relevant for the successful integration of ePC in standard oncology care.
A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of fatigue and pain among patients with metastatic solid tumors treated with cabozantinib.
Authors: Myat M. Han, Kyaw Zin Thein, Myo Zaw, Luke D'Cunha, Abhilash Perisetti, Fred L. Hardwicke, Lukman Tijani
Journal: Journal of Clinical Oncology (2017)

214 Background: Fatigue and pain notably contributed to the quality of life of cancer patients undergoing chemotherapy. Cabozantinib inhibits the activity of VEGFR, AXL, MET and other receptor tyrosine kinases which are essential in tumor development and progression. Yet the impact of this agent on fatigue and pain is a considerable safety concern. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine these risks. Methods: MEDLINE, EMBASE databases and meeting abstracts from inception to March 2017 were queried. Phase 3 RCTs that mention fatigue, asthenia, back pain, pain in arms and legs, arthralgia, muscle spasm and bone and musculoskeletal pain as adverse effects were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio with 95% confidence interval (CI). Results: Three phase 3 RCTs with a total of 1999 patients were eligible for analysis. Studies compared cabozantinib (C) vs everolimus, C vs placebo, C vs prednisone, were included in the analysis. The relative risks (RR) of all-grade adverse effects were as follows: fatigue, 1.34 (95% CI: 1.19- 1.50, p &lt; 0.0001); asthenia, 1.48 (95% CI: 1.06- 2.06, p = 0.02); back pain, 1.08 (95% CI: 0.84- 1.38, p = 0.52); pain in arms and legs, 1.44 (95% CI: 1.12- 1.84, p = 0.004); arthralgia, 0.98 (95% CI: 0.70- 1.36, p = 0.91); muscle spasm, 2.59 (95% CI: 1.63- 4.12, p &lt; 0.0001); bone pain, 1.22 (95% CI: 0.35- 4.21, p = 0.74); and musculoskeletal pain, 0.64 (95% CI: 0.42- 0.96, p = 0.03). The RR of high-grade adverse effects were as follows: fatigue, 1.84 (95% CI: 1.36- 2.48, p &lt; 0.0001); asthenia, 2.02 (95% CI: 1.37- 2.99, p &lt; 0.0001); back pain, 1.17 (95% CI: 0.69- 1.98, p = 0.54); pain in arms and legs, 2.93 (95% CI: 1.12- 7.63, p = 0.02); arthralgia, 0.82 (95% CI: 0.39- 1.70, p = 0.59); bone pain, 1.20 (95% CI: 0.28- 5.10, p = 0.79); and musculoskeletal pain, 1.34 (95% CI: 0.38- 4.64, p = 0.64). Conclusions: Cabozantinib increased the risk of all-grade and high-grade fatigue, asthenia and pain in arms and legs as well as all-grade muscle spasm whereas the risk of musculoskeletal pain was lower in the study arm, favoring cabozantinib.
Abstract 15287: Atypical Stress Cardiomyopathy is Associated With Lower Risk of Severe Shock at Diagnosis
Authors: Arash Nayeri, Nirmanmoh Bhatia, Eric Farber-Eger, Marcia Blair, Quinn Wells
Journal: Circulation (2016)

Introduction:  Typical stress cardiomyopathy is characterized by apical ballooning with relative preservation of basal segments. However, atypical variants with variable wall motion abnormalities (WMA) are increasingly recognized. Whether patients presenting with atypical variants of stress cardiomyopathy have distinctive clinical outcomes remains largely unknown.   Hypothesis:  Atypical variants of stress cardiomyopathy are associated with a more favorable hemodynamic status and lower mortality compared to the typical form.   Methods:  The study included all adult subjects diagnosed with stress cardiomyopathy (Mayo Clinic criteria) at a large medical center between 2005 and 2015. Atypical variants were defined by a midventricular, basal, and/or focal distribution of WMA. The primary outcome was death within 30 days of index diagnosis. Severe shock at diagnosis, defined as the need for vasopressors or mechanical circulatory support, was assessed as the secondary outcome.   Results:  Three hundred and six subjects met the inclusion criteria,  Table 1.  Death and severe shock occurred in in 43 (14%) and 90 (29%) of subjects, respectively. In multivariable logistic regression adjusting for age, Charlson Comorbidity Index, triggering mechanism, sepsis, and initial ejection fraction, atypical variants were not associated with 30-day mortality (OR=0.35, 95% CI=0.09-1.35, p=0.128). However, atypical stress cardiomyopathy was associated with lower odds of severe shock (OR=0.37, 95% CI=0.15-0.95, p=0.039).   Conclusions:  Atypical variants of stress cardiomyopathy may be associated with lower likelihood of severe shock at diagnosis.   Table 1.  Clinical characteristics.  Data are presented as median (IQR) for continuous variables and count (percentage) for categorical variables. N represents the number of non-missing values.   a  Wilcoxon Rank Sum test   b  Pearson’s Chi-Squared test
Characteristics of urgent palliative cancer care consultations encountered by radiation oncologists.
Authors: Muhammad Mohsin Fareed, Monica Shalini Krishnan, Alexander Spektor, Mai Anh Huynh, Yaseer Mohammed Khouj, Lauren Michelle Hertan, Alexandra Nichipor, Tracy A. Balboni
Journal: Journal of Clinical Oncology (2017)

135 Background: Palliative radiation therapy(PRT)is often employed in patients with advanced cancers requiring urgent consultation given the rapidity of presentation.We report on characteristics of urgent palliative oncologic issues encountered by radiation oncologists(RO). Methods: We prospectively evaluated patterns of presentation in162 consecutive consultations for urgent PRT at 3 centers from 5/19/14 to 9/26/14.Survey of palliative care issues was completed by physicians/nurse practitioners including assessment of reasons for urgent radiation oncology consultation,disease presentation characteristics and site of RT delivery.Response rate was 86% with 140 of 162 responses received. Results: Median age of patients was 63 years(29-89)with 39% &gt; 65, 41% from 50-65 and 20% &lt; 50 years;56% were males and 44% females. Most were married(62%)and 30% non-Caucasians.48% had ECOG PS 0-1,whereas it was 2, 3 and 4 in 24%,9% and 3%.Primary cancer diagnoses were lung (28%),breast(13%),prostate(10%),melanoma(10%),sarcoma(7%) and other diagnoses in 32%.Pain was predominant reason for consult(57%)followed by brain metastases(29%),spinal cord/cauda compression (13%),dyspnea (10%),bleeding (8%),bone fracture(4%)and dysphagia(2%).Clinicians managed pain (69%),neurologic symptoms(51%),fatigue (49%),intestinal(21%),respiratory (19%) symptoms,bleeding (14%),insomnia (13%),nausea/vomiting(12%)and dysphagia(6%).Patients presented at all stages 79% at the time of their diagnosis of metastatic cancer,63% with an established ( &gt; 1 month) metastatic cancer diagnosis and continuing to further cancer therapies and 17% proceeding to hospice care without further anti-cancer therapy after PRT. Conclusions: Radiation oncologists care for patients across time course of metastatic cancer diagnosis managing variety of urgent oncologic issues,most commonly metastases causing pain followed by brain metastases and cord compression.They also manage cancer-related symptoms,mostly pain,neurological symptoms and fatigue.These findings point to need for palliative care to be well integrated into radiation oncology practice including education and systems of care.